Barrett G. Levesque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barrett G. Levesque has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- William J. Sandborn
Division of Gastroenterology, Department of Medicine, University of California San Diego , La Jolla, CA
4 shared publications Gy Zou
Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8
3 shared publications- John K. MacDonald
University of Western Ontario; Department of Medicine; London ON Canada
3 shared publications Sigrid A Nelson
Robarts Clinical Trials Inc; San Diego California USA
3 shared publicationsB. G. Feagan
Robarts Clinical Trials, University of Western Ontario, London, ON, Canada
2 shared publications- Brian G. Feagan
Robarts Research Institute, University of Western Ontario, London, ON, Canada
2 shared publications
Latest Publications
- 21 September 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (10) , 1200-1210
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe the role of PRO instruments in evaluation of claims for product labelling. However, no validated PRO exists for ulcerative colitis. To investigate whether the PROs from the Mayo Clinic Score (MCS) for UC can be modified, to develop an interim PRO for use in clinical trials, alone or in combination with endoscopy. Data from an induction trial of a mesalazine (mesalamine) formulation were used to compare effect sizes between mesalazine and placebo for PRO items (stool frequency and rectal bleeding) alone and in combination with endoscopy. The operating properties of the PRO were validated using data from a phase 2 trial of MLN02, a humanised antibody to the α4β7 integrin in patients with UC. A two-item PRO (PRO2) consisting of rectal bleeding = 0 and stool frequency ≤1 or ≤2, combined with an endoscopy subscore ≤1 yielded statistically significant differences between active drug and placebo. This combination yielded the most similar effect sizes and placebo rates for remission, compared to the primary trials. Use of PRO items alone yielded high placebo remission rates in both data sets, although rates were lower when the items were combined and remission defined as PRO2 = 0. Patient-reported outcomes items derived from the Mayo Clinic Score combined with endoscopy as a co-primary endpoint may be an appropriate interim outcome measure for ulcerative colitis trials.
- 21 September 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (10) , 1200-1210
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe the role of PRO instruments in evaluation of claims for product labelling. However, no validated PRO exists for ulcerative colitis. To investigate whether the PROs from the Mayo Clinic Score (MCS) for UC can be modified, to develop an interim PRO for use in clinical trials, alone or in combination with endoscopy. Data from an induction trial of a mesalazine (mesalamine) formulation were used to compare effect sizes between mesalazine and placebo for PRO items (stool frequency and rectal bleeding) alone and in combination with endoscopy. The operating properties of the PRO were validated using data from a phase 2 trial of MLN02, a humanised antibody to the α4β7 integrin in patients with UC. A two-item PRO (PRO2) consisting of rectal bleeding = 0 and stool frequency ≤1 or ≤2, combined with an endoscopy subscore ≤1 yielded statistically significant differences between active drug and placebo. This combination yielded the most similar effect sizes and placebo rates for remission, compared to the primary trials. Use of PRO items alone yielded high placebo remission rates in both data sets, although rates were lower when the items were combined and remission defined as PRO2 = 0. Patient-reported outcomes items derived from the Mayo Clinic Score combined with endoscopy as a co-primary endpoint may be an appropriate interim outcome measure for ulcerative colitis trials.
- 8 April 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4
MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease
- 8 April 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4
MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease
- 26 March 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 3
Vedolizumab for induction and maintenance of remission in Crohn’s disease
- 26 March 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 3
Vedolizumab for induction and maintenance of remission in Crohn’s disease
- 2 January 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 1
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis
- 2 January 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 1
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis
- 27 October 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 41 (1) , 77-86
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
Summary: Background: The Crohn's Disease Activity Index (CDAI) is a measure of disease activity based on symptoms, signs and a laboratory test. The US Food and Drug Administration has indicated that patient reported outcomes (PROs) should be the primary outcome in randomised controlled trials for Crohn's disease (CD).Aim: As no validated PRO exists for CD, to investigate whether CDAI diary card items could be modified for this purpose.Methods: Data from a trial of rifaximin‐extended intestinal release were used to identify cut‐points for stool frequency, pain and general well‐being using receiver operating characteristic curves with CDAI <150 as criterion. The operating properties of 2‐ and 3‐item PRO were evaluated using data from a trial of methotrexate in CD. Regression analysis determined PRO2 and PRO3 scores that correspond to CDAI‐defined thresholds of 150, 220 and 450 and changes of 50, 70 and 100 points.Results: Optimum cut‐points for CDAI remission were mean daily stool frequency ≤1.5, abdominal pain ≤1, and general well‐being score of ≤1 (areas under the ROC curve 0.79, 0.91 and 0.89, respectively). The effect estimates were similar using 2‐ and 3‐item PROs or CDAI. PRO2 and PRO3 values corresponding to CDAI scores of 150, 220 and 450 points were 8, 14, 34 and 13, 22, 53. The corresponding values for CDAI changes of 50, 70 and 100, were 2, 5, 8 and 5, 9, 14. Responsiveness to change was similar for both PROs.Conclusion: Patient reported outcomes derived from CDAI diary items may be appropriate for use in clinical trials for CD.
- 27 October 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 41 (1) , 77-86
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
Summary: Background: The Crohn's Disease Activity Index (CDAI) is a measure of disease activity based on symptoms, signs and a laboratory test. The US Food and Drug Administration has indicated that patient reported outcomes (PROs) should be the primary outcome in randomised controlled trials for Crohn's disease (CD).Aim: As no validated PRO exists for CD, to investigate whether CDAI diary card items could be modified for this purpose.Methods: Data from a trial of rifaximin‐extended intestinal release were used to identify cut‐points for stool frequency, pain and general well‐being using receiver operating characteristic curves with CDAI <150 as criterion. The operating properties of 2‐ and 3‐item PRO were evaluated using data from a trial of methotrexate in CD. Regression analysis determined PRO2 and PRO3 scores that correspond to CDAI‐defined thresholds of 150, 220 and 450 and changes of 50, 70 and 100 points.Results: Optimum cut‐points for CDAI remission were mean daily stool frequency ≤1.5, abdominal pain ≤1, and general well‐being score of ≤1 (areas under the ROC curve 0.79, 0.91 and 0.89, respectively). The effect estimates were similar using 2‐ and 3‐item PROs or CDAI. PRO2 and PRO3 values corresponding to CDAI scores of 150, 220 and 450 points were 8, 14, 34 and 13, 22, 53. The corresponding values for CDAI changes of 50, 70 and 100, were 2, 5, 8 and 5, 9, 14. Responsiveness to change was similar for both PROs.Conclusion: Patient reported outcomes derived from CDAI diary items may be appropriate for use in clinical trials for CD.
- 26 September 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (2) , 299-312
The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review
Crohn’s disease (CD) is associated with a substantial healthcare burden that affects the patient, healthcare systems and society in general. To provide a systematic evaluation of published data relating to the economic and health-related quality-of-life (HRQoL) burden of CD in selected European countries (Germany, France, UK, Italy, Spain) and the USA since 2000. We undertook a systematic review of publications relating to CD, its economic burden and impact on HRQoL. Research questions focused on the disease costs from a societal perspective and HRQoL burden in adults and pediatric/adolescent patients according to disease stage/severity. Total, direct and indirect costs were identified, as well as the impact of CD on HRQoL measured using both generic and disease-specific instruments. Overall, 61 publications met the research criteria (38 on costs, 23 on HRQoL). CD in the USA and Europe together was associated with annual total costs of nearly €30 billion, more than half due to indirect costs. HRQoL was consistently and statistically significantly lower among CD patients compared with normal populations, due to physical, emotional and social effects. CD is a global health problem with high societal costs and substantial HRQoL burden. High-value care pathways including cost-effective therapies will help to induce and maintain remission, reduce complications of disease and improve HRQoL.
- 26 September 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (2) , 299-312
The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review
Crohn’s disease (CD) is associated with a substantial healthcare burden that affects the patient, healthcare systems and society in general. To provide a systematic evaluation of published data relating to the economic and health-related quality-of-life (HRQoL) burden of CD in selected European countries (Germany, France, UK, Italy, Spain) and the USA since 2000. We undertook a systematic review of publications relating to CD, its economic burden and impact on HRQoL. Research questions focused on the disease costs from a societal perspective and HRQoL burden in adults and pediatric/adolescent patients according to disease stage/severity. Total, direct and indirect costs were identified, as well as the impact of CD on HRQoL measured using both generic and disease-specific instruments. Overall, 61 publications met the research criteria (38 on costs, 23 on HRQoL). CD in the USA and Europe together was associated with annual total costs of nearly €30 billion, more than half due to indirect costs. HRQoL was consistently and statistically significantly lower among CD patients compared with normal populations, due to physical, emotional and social effects. CD is a global health problem with high societal costs and substantial HRQoL burden. High-value care pathways including cost-effective therapies will help to induce and maintain remission, reduce complications of disease and improve HRQoL.
- 1 September 2014
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 43 (3) , 479-494
An Update on Anti-TNF Agents in Ulcerative Colitis
- 1 September 2014
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 43 (3) , 479-494
An Update on Anti-TNF Agents in Ulcerative Colitis
- 7 August 2014
- Published by Wiley
Histologic scoring indices for evaluation of disease activity in ulcerative colitis
- 7 August 2014
- Published by Wiley
Histologic scoring indices for evaluation of disease activity in ulcerative colitis
- 5 March 2014
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 16 (4) , 1-8
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that “one size does not fit all”, we focused on the first prospective studies investigating the novel approach in IBD of ‘target concentration adjusted dosing’ and personalized medicine.
- 5 March 2014
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 16 (4) , 1-8
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that “one size does not fit all”, we focused on the first prospective studies investigating the novel approach in IBD of ‘target concentration adjusted dosing’ and personalized medicine.
- Open Access
- 1 June 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (6) , 1443-1444
Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohnʼs disease
- 1 June 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (6) , 1443-1444
Open AccessMycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohnʼs disease